An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma

Therapeutic application of monoclonal antibodies in cancer: advances and challenges

(2012) H. Modjtahedi et al.   BRITISH MEDICAL BULLETIN

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

T cells become licensed in the lung to enter the central nervous system

(2012) Francesca Odoardi et al.   NATURE

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF- 

(2011) J. Lohr et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies engage T cells for antitumor immunotherapy

(2011) Bryan D Choi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

(2010) Claudia Bluemel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients

(2010) B. Palermo et al.   CANCER RESEARCH

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

Cytotoxic Enhancement of a Bispecific Diabody by Format Conversion to Tandem Single-chain Variable Fragment (taFv)

(2010) Ryutaro Asano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival

(2010) Isaac Yang et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

What's fueling the biotech engine—2008

(2009) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

(2008) M. Amann et al.   CANCER RESEARCH

Fully human antibodies from transgenic mouse and phage display platforms

(2008) Nils Lonberg   CURRENT OPINION IN IMMUNOLOGY

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients

(2008) Paola Nisticò et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

(2008) Khalid Al-Nedawi et al.   NATURE CELL BIOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE